22 86

Cited 0 times in

Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database

DC Field Value Language
dc.contributor.author김남균-
dc.contributor.author김아영-
dc.contributor.author신재일-
dc.contributor.author이금화-
dc.contributor.author정세용-
dc.contributor.author정조원-
dc.contributor.author최재영-
dc.date.accessioned2022-05-09T16:52:43Z-
dc.date.available2022-05-09T16:52:43Z-
dc.date.issued2022-02-
dc.identifier.issn1752-8054-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/188259-
dc.description.abstractOn October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID-19), increasing remdesivir prescriptions worldwide. However, potential cardiovascular (CV) toxicities associated with remdesivir remain unknown. We aimed to characterize the CV adverse drug reactions (ADRs) associated with remdesivir using VigiBase, an individual case safety report database of the World Health Organization (WHO). Disproportionality analyses of CV-ADRs associated with remdesivir were performed using reported odds ratios and information components. We conducted in vitro experiments using cardiomyocytes derived from human pluripotent stem cell cardiomyocytes (hPSC-CMs) to confirm cardiotoxicity of remdesivir. To distinguish drug-induced CV-ADRs from COVID-19 effects, we restricted analyses to patients with COVID-19 and found that, after adjusting for multiple confounders, cardiac arrest (adjusted odds ratio [aOR]: 1.88, 95% confidence interval [CI]: 1.08-3.29), bradycardia (aOR: 2.09, 95% CI: 1.24-3.53), and hypotension (aOR: 1.67, 95% CI: 1.03-2.73) were associated with remdesivir. In vitro data demonstrated that remdesivir reduced the cell viability of hPSC-CMs in time- and dose-dependent manners. Physicians should be aware of potential CV consequences following remdesivir use and implement adequate CV monitoring to maintain a tolerable safety margin.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherWileyBlackwell Pub.-
dc.relation.isPartOfClinical and Translational Science-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdenosine Monophosphate / adverse effects-
dc.subject.MESHAdenosine Monophosphate / analogs & derivatives*-
dc.subject.MESHAlanine / adverse effects-
dc.subject.MESHAlanine / analogs & derivatives*-
dc.subject.MESHAntiviral Agents / adverse effects*-
dc.subject.MESHCOVID-19 / drug therapy*-
dc.subject.MESHCardiovascular Diseases / chemically induced*-
dc.subject.MESHDatabases, Factual-
dc.subject.MESHHumans-
dc.subject.MESHMyocytes, Cardiac / drug effects-
dc.subject.MESHPharmacovigilance*-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSARS-CoV-2*-
dc.subject.MESHWorld Health Organization-
dc.titleCardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Thoracic and Cardiovascular Surgery (흉부외과학교실)-
dc.contributor.googleauthorSe Yong Jung-
dc.contributor.googleauthorMin Seo Kim-
dc.contributor.googleauthorHan Li-
dc.contributor.googleauthorKeum Hwa Lee-
dc.contributor.googleauthorAi Koyanagi-
dc.contributor.googleauthorMarco Solmi-
dc.contributor.googleauthorAndreas Kronbichler-
dc.contributor.googleauthorElena Dragioti-
dc.contributor.googleauthorKalthoum Tizaoui-
dc.contributor.googleauthorSarah Cargnin-
dc.contributor.googleauthorSalvatore Terrazzino-
dc.contributor.googleauthorSung Hwi Hong-
dc.contributor.googleauthorRamy Abou Ghayda-
dc.contributor.googleauthorNam Kyun Kim-
dc.contributor.googleauthorSeo Kyoung Chung-
dc.contributor.googleauthorLouis Jacob-
dc.contributor.googleauthorJoe-Elie Salem-
dc.contributor.googleauthorDong Keon Yon-
dc.contributor.googleauthorSeung Won Lee-
dc.contributor.googleauthorKarel Kostev-
dc.contributor.googleauthorAh Young Kim-
dc.contributor.googleauthorJo Won Jung-
dc.contributor.googleauthorJae Young Choi-
dc.contributor.googleauthorJin Soo Shin-
dc.contributor.googleauthorSoon-Jung Park-
dc.contributor.googleauthorSeong Woo Choi-
dc.contributor.googleauthorKiwon Ban-
dc.contributor.googleauthorSung-Hwan Moon-
dc.contributor.googleauthorYun Young Go-
dc.contributor.googleauthorJae Il Shin-
dc.contributor.googleauthorLee Smith-
dc.identifier.doi10.1111/cts.13168-
dc.contributor.localIdA00355-
dc.contributor.localIdA04727-
dc.contributor.localIdA02142-
dc.contributor.localIdA04622-
dc.contributor.localIdA03628-
dc.contributor.localIdA03720-
dc.contributor.localIdA04174-
dc.relation.journalcodeJ04188-
dc.identifier.eissn1752-8062-
dc.identifier.pmid34719115-
dc.contributor.alternativeNameKim, Nam Kyun-
dc.contributor.affiliatedAuthor김남균-
dc.contributor.affiliatedAuthor김아영-
dc.contributor.affiliatedAuthor신재일-
dc.contributor.affiliatedAuthor이금화-
dc.contributor.affiliatedAuthor정세용-
dc.contributor.affiliatedAuthor정조원-
dc.contributor.affiliatedAuthor최재영-
dc.citation.volume15-
dc.citation.number2-
dc.citation.startPage501-
dc.citation.endPage513-
dc.identifier.bibliographicCitationClinical and Translational Science, Vol.15(2) : 501-513, 2022-02-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.